Millions of doses of a new, cheap coronavirus vaccine will soon be available in India, and they will arrive with one distinction neither Moderna nor Pfizer can claim: They're patent-free. The new CORBEVAX inoculation, which was developed in Texas with decades-old technology and little support from the U.S. government, received emergency use authorization last week from India's drug regulation agency. The researchers behind the vaccine stand with little to gain financially. "We don't own any intellectual property," said Dr. Peter Hotez, a researcher who helped lead the vaccine's development. Human rights campaigners are pressuring pharmaceutical companies to transfer new vaccine technology to speed global access to shots. And while doubts linger about CORBEVAX ... its development, outside the path of typical pharmaceutical development and stripped of the same financial incentives for inventors, represents a model for others. About 59 percent of the world's population has received at least one dose of a vaccine. But fewer than 9 percent of residents in low-income countries have received a dose. To this day, countries like India remain without access to the mRNA vaccines produced by Pfizer-BioNTech and Moderna, which have largely been purchased and distributed by wealthy countries. Boosters, and even fourth doses, are being administered in rich countries before access to first and second doses are available worldwide.